Apellis Pharmaceuticals, Inc. (APLS)

Apellis Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 27, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	2,679	3,178	3,969	7,093	5,718	4,603
Market Cap Growth	-24.45%	-19.93%	-44.04%	24.06%	24.22%	6.25%
Enterprise Value	2,686	3,173	4,036	6,737	5,123	4,385
Last Close Price	20.96	25.12	31.91	59.86	51.71	47.28
PE Ratio	121.57	141.97	-	-	-	-
PS Ratio	2.67	3.17	5.08	17.89	75.81	69.15
PB Ratio	7.17	8.59	17.37	36.47	33.66	23.17
P/TBV Ratio	7.24	8.59	17.37	36.47	33.66	23.17
P/FCF Ratio	59.52	70.61	-	-	-	-
P/OCF Ratio	59.11	70.12	-	-	-	-
EV/Sales Ratio	2.68	3.16	5.17	16.99	67.92	65.87
EV/EBITDA Ratio	47.13	55.69	-	-	-	-
EV/EBIT Ratio	48.46	57.26	-	-	-	-
EV/FCF Ratio	59.67	70.50	-	-	-	-
Debt / Equity Ratio	1.28	1.28	2.06	0.57	0.66	1.06
Debt / EBITDA Ratio	7.03	7.03	-	-	-	-
Debt / FCF Ratio	10.54	10.54	-	-	-	-
Net Debt / Equity Ratio	0.02	0.02	0.24	-1.26	-2.62	-2.47
Net Debt / EBITDA Ratio	0.12	0.12	-0.33	0.48	0.75	0.92
Net Debt / FCF Ratio	0.15	0.15	-0.61	0.41	0.87	0.87
Asset Turnover	1.02	1.02	0.93	0.51	0.09	0.07
Inventory Turnover	3.50	3.50	3.63	3.15	6.35	-
Quick Ratio	2.59	2.59	3.71	2.34	3.56	5.93
Current Ratio	3.14	3.14	4.25	3.10	4.29	6.25
Return on Equity (ROE)	7.48%	7.48%	-93.55%	-290.14%	-353.93%	-370.20%
Return on Assets (ROA)	3.53%	3.53%	-12.32%	-41.73%	-45.27%	-36.39%
Return on Invested Capital (ROIC)	13.32%	15.62%	-142.16%	-	-	-
Return on Capital Employed (ROCE)	7.40%	7.40%	-23.60%	-95.60%	-100.30%	-71.50%
Earnings Yield	0.84%	0.70%	-4.98%	-7.45%	-11.41%	-16.21%
FCF Yield	1.68%	1.42%	-2.22%	-8.39%	-9.01%	-12.26%
Buyback Yield / Dilution	-4.80%	-4.80%	-4.40%	-11.84%	-25.70%	-12.32%

Updated Feb 24, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q